Actively Recruiting
Neuroplasticity Biomarkers in Aphasia
Led by University of Wisconsin, Madison · Updated on 2025-10-23
90
Participants Needed
1
Research Sites
219 weeks
Total Duration
On this page
Sponsors
U
University of Wisconsin, Madison
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.
CONDITIONS
Official Title
Neuroplasticity Biomarkers in Aphasia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages 40 to 90 years
- Right-handed before stroke
- Proficient English speakers
- History of a single ischemic stroke in the middle cerebral artery territory lateralized to the left or right cerebral hemisphere
- Presence of aphasia for chronic stroke enrollment (Aims 2-3)
- Capacity to understand the study and provide informed consent
- Acute or subacute stroke at Aim 1 enrollment; stroke at least 12 months old for Aims 2-3
- Medically stable
You will not qualify if you...
- History of significant medical or neurological disorders other than stroke
- History of significant or poorly controlled psychiatric disorders
- Current abuse of alcohol or drugs, prescription or otherwise
- Clinically significant and uncorrected vision or hearing loss
- Treatments other than standard stroke care such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications, cholesterol-lowering agents, thrombolytics (e.g., tPA), anticoagulants like Heparin or Warfarin/Coumadin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UW School of Medicine and Public Health
Madison, Wisconsin, United States, 53792
Actively Recruiting
Research Team
H
Haley Dresang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here